After being rejected twice, Horizon pushes Depomed to accept its €2.7Bn offer

13/07/2015 - 1 minute

Horizon Pharma is getting anxious and has offered the substantial amount of €2.7Bn to buy its American competitor Depomed. The Irish drug-maker plans to add the US-based firm to its shopping list just after enrolling Hyperion Therapeutics, the company that was purchased only one month ago.

Dublin-based Horizon has been pursuing Depomed lately, but the American company is playing hard to get. After been rebuffed twice, Horizon has decided to address the shareholders directly, to whom the former has offered €26.2 per share, 42% premium to Depomed’s closing price last Monday. Horizon expects the stockholders to listen to reason and understand the benefits this takeover transition will bring.

Nevertheless, Depomed’s Board of Directors is not convinced with the unsolicited proposal and, in a statement, has warned its shareholders that they would only own 27% of the combined company. The American managers believe in the potential of the company to run on its own, and therefore suggested a bigger piece of a perhaps smaller cake to the investors.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member